Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalizing arthritis treatment: genes may predict drug success

NCT ID NCT07388407

Knowledge-focused Sponsor: Foundation University Islamabad Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how genetic differences influence the effectiveness and side effects of leflunomide, a common rheumatoid arthritis drug. Researchers will recruit 110 Pakistani patients starting leflunomide and track their disease activity and side effects over six months. By analyzing DNA from blood samples, they hope to find genetic markers that predict who responds well and who experiences toxicity, potentially leading to more personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
leflunomide
What this could lead to
If successful, this could help doctors predict which rheumatoid arthritis patients will benefit most from leflunomide and who might have side effects.
What could go wrong
This is an early observational study with only 110 participants. Results may not apply to all populations, and the genetic markers found may not reliably predict outcomes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient of RA taking Leflunomide

Ages

20 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10 * Pakistani individuals * between ages of 20-75 years * New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available Exclusion Criteria: * Patients not willing to participate/ consent not given * Patients below the age of 20 * Non- Pakistani origin * Taking another DMARD simultaneously * Compromised renal and hepatic functions * Cognitive impairment, neurological disease * Pregnant/ lactating patients * Patients having inflammatory bowel disease/ Irritable bowel syndrome * Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rhematoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rhematoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fauji Foundation Hospital, Rawalpindi

    RECRUITING

    Rawalpindi, Punjab Province, 46000, Pakistan

  • Shifa International Hospital

    COMPLETED

    Islamabad, Punjab Province, 44000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.